Helus Pharma reports $148M net loss, closes $50M offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
June 29, 2026 7:40 AM EDT- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New Drug Application in 20281,2,3 -
- Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (MDD) has surpassed 88% enrollment and is on track for topline data readout in Q4 20262,3 -
- HLP003 Phase 2 data demonstrated durability at 12... More
